DoMore Diagnostics develops AI-driven diagnostic tools for precision medicine to personalize cancer treatment decisions. The company utilizes digital pathology and novel algorithms to create prognostic assays, such as Histotype Px® Colorectal. This technology aims to provide objective prognosis for cancer patients, reducing overtreatment and undertreatment.
Funding
$12.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EAFounders
Product
Problem
Current cancer diagnostics lack objective methods for accurately predicting disease progression and prognosis, hindering the development of personalized treatment plans and potentially impacting patient outcomes. This limitation stems from the reliance on subjective assessments and the absence of precise tools for gauging individual patient risk.
Solution
DoMore Diagnostics leverages artificial intelligence to provide a more objective and accurate assessment of cancer progression and prognosis. By applying advanced AI algorithms to digital pathology data, the company aims to transform cancer diagnostics, enabling clinicians to make more informed treatment decisions tailored to the individual patient. This approach seeks to reduce both over- and under-treatment by providing a new system for cancer prognosis. The AI-driven technology analyzes complex patterns in patient data to predict disease trajectory and identify optimal treatment strategies.
Target Audience
The primary target audience includes oncologists, pathologists, and pharmaceutical companies involved in cancer drug development.
Features
- AI-powered analysis of digital pathology images for objective cancer prognosis
- Algorithms trained on data from leading universities (University in Oslo, Oxford University and University College of London)
- Identification of patterns indicative of cancer progression and treatment response
- Integration with existing digital pathology workflows